From October 8 to 10 2024, the CPHI Worldwide 2024 will be held at Fiera Milano in Italy. With the theme of "The Partner of Choice", Henlius will showcase 6 launched products, its robust biologic pipeline and integrated global biopharmaceutical platform at booth #14A20.
For 35 years, CPHI Worldwide has been at the heart of global pharmaceutical industry and is the world's largest gathering of the industry's leading companies and investors from around the world, with numerous collaborative events taking place during the conference. Last year's CPHI Barcelona 2023 featured around 2,400 companies and attracted close to 54,000 industry professionals.
As a global biopharmaceutical company, Henlius is committed to offering high-quality, affordable, and innovative biologics for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases and has pro-actively built a diversified and high-quality product pipeline covering over 50 molecules. Up to date, Henlius has 6 products launched in China, 3 approved for marketing in overseas markets, 24 indications approved worldwide, benefiting over 650,000 patients and reaching 48 countries and regions in Asia, Europe, Latin America, North America and Oceania.
Henlius continuously enhances the development and operational efficiency of its integrated R&D, production, and commercialization platform. Through various measures to improve product accessibility, the company drives the commercial growth of core products and achieves sustained high-quality profitability. Meanwhile, the company joined hands with international partners such as Accord, Eurofarma, KGbio and Organon to accelerate overseas commercialization of its products, collectively advancing the innovation and globalization of China's biopharmaceutical industry.
During the exhibition, the company will showcase 6 launched products, including HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), a China-developed mAb biosimilar approved approved in all China, Europe and the U.S., and its innovative product HANSIZHUANG (serplulimab), the world’s first anti-PD-1 mAb for the first-line treatment of small cell lung cancer.
Henlius' core oncology product HANQUYOU has been approved in 48 countries and regions around the world, making it the China-developed mAb biosimilar with the most marketing approvals. Until now, it has benefit more than 210,000 patients. In June 2024, HANQUYOU made its first delivery to Saudi Arabia, poised to be the first Chinese mAb to enter the Middle Eastern market. The innovative product HANSIZHUANG has been approved in China for the treatment of microsatellite instability-high (MSI-H) solid tumors, squamous non-small cell lung cancer, extensive-stage small cell lung cancer, and esophageal squamous cell carcinoma. It has also been approved in Southeast Asian countries such as Indonesia, Thailand, and Cambodia, benefiting approximately 80,000 patients in total. In January 2024, Henlius has completed the first international shipment of HANSIZHUANG, opening a new chapter in benefiting patients worldwide with this product.
In addition, Henlius achieved a number of milestones in business development. Regarding HLX78 (lasofoxifene), an investigational novel targeted endocrine therapy in clinical development, the company expanded its collaboration with Sermonix in all of Asia. Furthermore, Henlius reached cooperation with Convalife to commercialize neratinib (trade name: HANNAIJIA), further expanding the company’s treatment landscape for breast cancer.
Henlius is dedicated to offering high-quality, affordable, and innovative biologics for patients worldwide, focusing on high-quality innovative outcomes and making efforts in the oncology field. The company continues to expand international collaborations and warmly invites you to visit booth #14A20 at Fiera Milano in Italy for more discussions. Let’s explore the future and opportunities together to create a bright future.